SirtexMedical has completed patient recruitment for its SIRFLOX study, designed to assess SIR-Spheres microspheres as first-line treatment for colorectal liver metastases.

The world’s largest interventional oncology study has enrolled over 500 patients with inoperable liver metastases from primary colorectal cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Sirtex Medical president Mike Mangano said that the company was committed to large, randomised controlled trials to confirm the results from various, smaller, peer-reviewed studies that have established the effectiveness of SIR-Spheres microspheres.

"We anticipate that the data from the SIRFLOX study will provide sufficient proof to the oncology community that combining chemotherapy and internal radiation therapy earlier in the treatment algorithm will benefit patients," Mangano added.

The study will assess the effectiveness of first-line treatment strategy of standard-of-care chemotherapy along with SIR-Spheres microspheres against chemotherapy alone in delaying cancer progression in patients with inoperable liver metastases from primary colorectal cancer.

See Also:

The company expects the primary results of the study to be released in late 2014.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SIRFLOX investigator and University of Maryland School of Medicine vascular and interventional radiology division interim director said, "We are excited to be the top enrolling US site in this landmark study and look forward to seeing the results, which we believe will help further guide the oncology community in best practice treatment for liver tumours from metastatic colorectal disease."

The patients with metastatic colorectal cancer showed high response rates when treated with Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres compared to other treatment forms in various clinical studies, the company claimed.

SIRT, also referred to as radioembolisation, delivers radiation doses to the tumor site directly in a minimally invasive treatment through a catheter.